Catechol-O-methyl transferase as a drug target for schizophrenia

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 3, 2012, Pages 282-291

  O'Tuathaigh, Colm M P ^a,b   Desbonnet, Lieve ^a   Lee, Peter ^c   Waddington, John L ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Antipsychotics; Catechol o methyltransferase; Cognition; Negative symptoms; Schizophrenia

Indexed keywords

ALANINE; AMPHETAMINE; CANNABIS; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; CATECHOLAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; DRONABINOL; METHIONINE; NEUROLEPTIC AGENT; PLACEBO; PROTEIN P300; PROTEIN P50; PSYCHOSTIMULANT AGENT; SERINE; TOLCAPONE; VALINE;

AGGRESSION; AMINO ACID SUBSTITUTION; ANHEDONIA; BEHAVIOR; CATECHOLAMINE METABOLISM; CHROMOSOME DELETION 22Q11; CLINICAL EXAMINATION; COGNITION; COGNITIVE DEFECT; DELUSION; DISEASE SEVERITY; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; DRUG USE; ENZYME ACTIVITY; ENZYME DEGRADATION; EVIDENCE BASED MEDICINE; EVOKED AUDITORY RESPONSE; GENE EXPRESSION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HALLUCINATION; HIPPOCAMPUS; HUMAN; HYPOTHESIS; NEGATIVE SYNDROME; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHENOTYPE; POSITIVE SYNDROME; PREFRONTAL CORTEX; PREPULSE INHIBITION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOM; TREATMENT RESPONSE; VELOCARDIOFACIAL SYNDROME; WORKING MEMORY;

EID: 84861725011     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712800672418     Document Type: Review

References (146)

1. Waddington, J.L.; Hennessy, R.J.; O'Tuathaigh, C.M.P.; Owoeye, O.; Russell, V. Schizophrenia and the lifetime trajectory of psychotic illness: developmental neuroscience and pathobiology. In: The origins of schizophrenia; Brown AS, Patterson PH, Eds.; Columbia University Press, New York, 2012.
2. Pelletier, M.; Achim, A. M.; Montoya, A.; Lal, S.; Lepage, M. Cognitive and clinical moderators of recognition memory in schizophrenia: a meta-analysis. Schizophr. Res., 2005, 74, 233-252.
3. Arguello, P.A.; Gogos, J.A. Modeling madness in mice: one piece at a time. Neuron, 2006, 52, 179-196.
4. Arguello, P.A.; Gogos, J.A. Cognition in mouse models of schizophrenia susceptibility genes. Schizophr. Bull., 2010, 36, 289-300.
5. Erlenmeyer-Kimling, L.; Rock, D.; Roberts, S.A.; Janal, M.; Kestenbaum, C.; Cornblatt, B.; Adamo, U.H.; Gottesman, I.I. Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: the New York High-Risk Project. Am. J. Psychiatry, 2000, 157, 1416-1422.
6. Niendam, T.A.; Bearden, C.E.; Rosso, I.M.; Sanchez, L.E.; Hadley, T.; Nuechterlein, K.H.; Cannon, T.D. A prospective study of childhood neurocognitive functioning in schizophrenic patients and their siblings. Am. J. Psychiatry, 2003, 160, 2060-2062.
7. Green, M.F.; Kern, R.S.; Heaton, R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res., 2004, 72, 41-51.
8. Keefe, R.S.; Poe, M.; Walker, T.M.; Kang, J.W.; Harvey, P.D. The schizophrenia cognition rating scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Am. J. Psychiatry, 2006, 163, 426-432.
9. Seeman, P. Dopamine D2 receptors as treatment targets in schizophrenia, Clin. Schizophr. Relay Psych., 2010, 4, 56-73.
10. Waddington, J.L.; O'Tuathaigh, C.M.P.; Remington, G.J. Pharmacology and neuroscience of antipsychotic drugs, In: Schizophrenia; Weinberger, D.R., Harrison, P.J., Eds.; Wiley-Blackwell, Oxford, 2011.
11. Marder, S.R.; Fenton, W. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr. Res., 2004, 72, 5-9.
12. Young, J.W.; Powell, S.B.; Geyer, M.A. Mouse pharmacological models of cognitive disruption relevant to schizophrenia. Neuropharmacology, 2011, 62(3), 1381-1390.
13. Papaleo, F.; Lipska, B.K.; Weinberger, D.R. Mouse models of genetic effects on cognition: relevance to schizophrenia. Neuropharmacology, 2011, 62(3), 1204-1220.
14. Kellendonk, C.; Simpson, E.H.; Kandel, E.R. Modeling cognitive endophenotypes of schizophrenia in mice. Trends Neurosci., 2009, 32, 347-358.
15. Kegeles, L.S.; Slifstein, M.; Xu, X.; Urban, N.; Thompson, J.L.; Moadel, T.; Harkavy-Friedman, J.M.; Gill, R.; Laruelle, M.; Abi-Dargham, A. Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F] fallypride positron emission tomography. Biol. Psychiatry, 2010, 68, 634-641.
16. Toda, M.; Abi-Dargham, A. Dopamine hypothesis of schizophrenia: making sense of it all. Curr. Psychiatry Rep., 2007, 9, 329-336.
17. Simpson, E.H.; Kellendonk, C.; Kandel, E. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron, 2010, 65, 585-596.
18. Williams, G.V.; Goldman-Rakic, P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature, 1995, 376, 572-575.
19. Tunbridge, E.M.; Harrison, P.J.; Weinberger, D.R. Catechol-o- methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol. Psychiatry, 2006, 60, 141-151.
20. Allen, N.C.; Bagade, S.; McQueen, M.B.; Ioannidis, J.P.; Kavvoura, F.K.; Khoury, M.J.; Tanzi, R.E.; Bertram, L. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat. Genet., 2008, 40, 827-834.
21. Tost, H.; Braus, D.F.; Hakimi, S., Ruf, M.; Vollmert, C.; Hohn, F.; Meyer-Lindenberg, A. Acute D2 receptor blockade induces rapid, reversible remodeling in human cortical-striatal circuits. Nat. Neurosci., 2010, 13, 920-922.
22. Waddington, J.L.; O'Tuathaigh, C.; O'Sullivan, G.; Tomiyama, K.; Koshikawa, N; Croke, D.T. Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface. Psychopharmacology, 2005, 181, 611-638.
23. Desbonnet, L.; Waddington, J.L.; O'Tuathaigh, C.M. Mice mutant for genes associated with schizophrenia: common phenotype or distinct endophenotypes? Behav. Brain Res., 2009, 204, 258-273.
24. Kirby, B.; Waddington, J.L.; O'Tuathaigh, C.M.P. Advancing a functional genomics for schizophrenia: psychopathological and cognitive phenotypes in mutants with gene disruption. Brain Res. Bull., 2010, 83, 162-176.
25. Ralph, R.J.; Varty, G.B.; Kelly, M.A.; Wang, Y.M.; Caron, M.G.; Rubinstein, M.; Grandy, D.K.; Low, M.J.; Geyer, M.A. The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J. Neurosci., 1999, 19, 4627-4633.
26. Ralph-Williams, R.J.; Lehmann-Masten, V.; Otero-Corchon, V.; Low, M.J.; Geyer, M.A. Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J. Neurosci., 2002, 22, 9604-9611.
27. Bay-Richter, C.; O'Tuathaigh, C.M.; O'Sullivan, G.; Heery, D.M.; Waddington, J.L.; Moran, P.M. Enhanced latent inhibition in dopamine receptor-deficient mice is sex-specific for the D1 but not D2 receptor subtype: implications for antipsychotic drug action. Int. J. Neuropsychopharmacol., 2009, 12, 403-414.
28. Papaleo, F.; Crawley, J.N.; Song, J.; Lipska, B.K.; Pickel, J.; Weinberger, D.R.; Chen, J. Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J. Neurosci., 2008, 28, 8709-8723.
29. Roth, J.A. Membrane-bound catechol-O-methyltransferase: a re-evaluation of its role in the O-methylation of the catecholamine neurotransmitters. Rev. Physiol. Biochem. Pharmacol., 1992, 120, 1-29.
30. Karayiorgou, M.; Simon, T.J.; Gogos, J.A. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nat. Rev. Neurosci., 2010, 11, 402-416.
31. Barnett, J.H.; Jones, P.B.; Robbins, T.W.; Muller, U. Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls. Mol. Psychiatry, 2007, 12, 502-509.
32. Chen, J.; Lipska, B.K.; Halim, N.; Ma, Q.D.; Matsumoto, M.; Melhem, S.; Kolachana, B.S.; Hyde, T.M.; Herman, M.M.; Apud, J.; Egan, M.F.; Kleinman, J.E.; Weinberger, D.R. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet., 2004, 75(5), 807-821.
33. Egan, M.F.; Goldberg, T.E.; Kolachana, B.S.; Callicott, J.H.; Mazzanti, C.M.; Straub, R.E.; Goldman, D.; Weinberger, D.R. Effect of COMTVal108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. USA, 2001, 98(12), 6917-6922.
34. Shifman, S.; Bronstein, M.; Sternfeld, M.; Pisante-Shalom, A.; Lev-Lehman, E.; Weizman, A.; Reznik, I.; Spivak, B.; Grisaru, N.; Karp, L.; Schiffer, R.; Kotler, M.; Strous, R.D.; Swartz-Vanetik, M.; Knobler, H.Y.; Shinar, E.; Beckmann, J.S.; Yakir, B.; Risch, N.; Zak, N.B.; Darvasi, A. A highly significant association between a COMT haplotype and schizophrenia. Am. J. Hum. Genet., 2002, 71(6), 1296-1302.
35. Hoenicka, J.; Garrido, E.; Martinez, I., Ponce, G.; Aragues, M.; Rodriguez-Jimenez, R.; Espana-Serrano, L.; Alvira-Botero, X.; Santos, J.L.; Rubio, G.; Jimenez-Arriero, M.A.; Palomo, T. Gender-specific COMT Val158Met polymorphism association in Spanish schizophrenic patients. Am. J. Med. Genet., 2010, 153B, 79-85.
36. Tee, S.F.; Tang, P.Y.; Loh, H.C. COMT haplotype analyses in Malaysian with schizophrenia. Psychiatry Research, 2011, 195(1-2), 83-84.
37. Munafo, M.R.; Bowes, L.; Clark, T.G.; Flint, J. Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: A meta-analysis of case-control studies. Mol. Psychiatry, 2005, 10(8), 765-770.
38. Okochi, T.; Ikeda, M.; Kishi, T.; Kawashima, K.; Kinoshita, Y.; Kitajima, T.; Kawashima, K.; Kinoshita, Y; Kitajima, T.; Yamanouchi, Y.; Tomita, M.; Inada, T.; Ozaki, N.; Iwata, N. Meta-analysis of association between genetic variants in COMT and 538 schizophrenia: an update. Schizophr. Res., 2009, 110, 140-148.
39. Jiang, H.; Xie, T.; Ramsden, D.B.; Ho, S.L. 2003. Human catechol- O-methyltransferase down-regulation by estradiol. Neuropharmacology, 2003, 45(7), 1011-1018.
40. Dempster, E.L.; Mill, J.; Craig, I.W.; Collier, D.A. 2006. The quantification of COMT mRNA in post mortem cerebellum tissue: Diagnosis, genotype, methylation and expression. BMC Med. Genet., 2006, 7, 10.
41. Chen, C.Y.; Lu, R.B.; Yeh, Y.W.; Shih, M.C.; Huang, S.Y. Association study of catechol-O-methyltransferase gene polymorphisms with schizophrenia and psychopathological symptoms in Han Chin. Genes Brain Behav., 2011, 10(3), 316-324.
42. Costas, J.; Sanjuán, J.; Ramos-Ríos, R.; Paz, E.; Agra, S.; Ivorra, J.L.; Páramo, M.; Brenlla, J.; Arrojo, M. Heterozygosity at catechol-O-methyltransferase Val158Met and schizophrenia: new data and meta-analysis. J. Psychiatr. Res., 2011, 45(1), 7-14.
43. Bilder, R.M.; Volavka, J.; Lachman, H.M.; Grace, A.A. The Catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology, 2004, 29, 1943-1961.
44. Durstewitz, D.; Seamans, J.K. The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-o-methyltransferase genotypes and schizophrenia. Biol. Psychiatry, 2008, 64, 739-749.
45. Lee, S.G.; Joo, Y.; Kim, B.; Chung, S.; Kim, H.L.; Lee, I.; Choi, B.; Kim, C.; Song, K. Association of Ala72Ser polymorphism with COMT enzyme activity and the risk of schizophrenia in Koreans. Hum. Genet., 2005, 116(4), 319-328.
46. Murphy, K.C.; Jones, L.A.; Owen, M.J. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch. Gen. Psychiatry, 1999, 56, 940-945.
47. Murphy, K.C.; Owen, M.J. Velo-cardio-facial syndrome: a model for understanding the genetics and pathogenesis of schizophrenia. Br. J. Psychiatry, 2001, 179, 397-402.
48. Prasad, S.E.; Howley, S.; Murphy, K.C. Candidate genes and the behavioral phenotype in 22q11.2 deletion syndrome. Dev. Disabil. Res. Rev., 2008, 14(1), 26-34
49. Kravariti, E.; Jacobson, C.; Morris, R.; Frangou, S.; Murray, R.M.; Tsakanikos, E.; Habel, A.; Shearer, J. Memory in intellectually matched groups of young participants with 22q11.2 deletion syndrome and those with schizophrenia. Res. Dev. Disabil., 2010, 31, 864-868.
50. Lajiness-O'Neill, R.R.; Beaulieu, I.; Titus, J.B.; Asamoah, A.; Bigler, E.D.; Bawle, E.V.; Pollack, R. Memory and learning in children with 22q11.2 deletion syndrome: evidence for ventral and dorsal stream disruption. Child Neuropsychol., 2005, 11, 55-71.
51. Gothelf, D.; Michaelovsky, E.; Frisch, A.; Zohar, A.H.; Presburger, G.; Burg, M.; Aviram-Goldring, A.; Frydman, M.; Yeshaya, J.; Shohat, M.; Korostishevsky, M.; Apter, A.; Weizman, A. Association of the low-activity COMT 158Met allele with ADHD and OCD in subjects with velocardiofacial syndrome. Int. J. Neuropsychopharmacol., 2007, 10, 301-308.
52. Gothelf, D.; Schaer, M.; Eliez, S. Genes, brain development and psychiatric phenotypes in velo-cardio-facial syndrome. Dev. Disabil. Res. Rev., 2008, 14, 59-68.
53. Meechan, D. W.; Tucker, E. S.; Maynard, T. M.; LaMantia, A. S. Diminished dosage of 22q11 genes disrupts neurogenesis and cortical development in a mouse model of 22q11 deletion/DiGeorge syndrome. Proc. Natl. Acad. Sci. USA, 2009, 106, 16434-16445.
54. Stark, K.L.; Xu, B.; Bagchi, A.; Lai, W.S.; Liu, H.; Hsu, R.; Wan, X.; Pavlidis, P.; Mills, A.A.; Karayiorgou, M.; Gogos, J.A. Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. Nat. Genet., 2008, 40, 751-760.
55. Bertolino, A.; Caforio, G.; Blasi, G.; De Candia, M.; Latorre, V.; Petruzzella, V.; Altamura, M.; Nappi, G.; Papa, S.; Callicott, J.H.; Mattay, V.S.; Bellomo, A.; Scarabino, T.; Weinberger, D.R.; Nardini, M. Interaction of COMT Val108/158 Met genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am. J. Psychiatry, 2004, 161, 1798-1805.
56. Wonodi, I.; Stine, O.C.; Mitchell, B.D.; Buchanan, R.W.; Thaker, G.K. Association between Val108/158 Met polymorphism of the COMT gene and schizophrenia. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2003, 120(1), 47-50.
57. Molero, P.; Ortuño, F.; Zalacain, M.; Patiño-García, A. Clinical involvement of catechol-o-methyltransferase polymorphisms in schizophrenia spectrum disorders: Influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics. J., 2007, 7, 418-426.
58. Collip, D.; Van Winkel, R.; Peerbooms, O.; Lataster, T.; Thewissen, V.; Lardinois, M.; Drukker, M.; Rutten, B.P.; Van Os, J.; Myin-Germeys, I. COMT Val158Met-stress interaction in psychosis: role of background psychosis risk. CNS Neurosci. Ther., 2011, 17(6), 612-619.
59. Low, N.C.; Hardy, J. What is a schizophrenic mouse? Neuron, 2007, 54, 348-349.
60. Van den Buuse, M. Modelling the positive symptoms of schizophrenia in genetically-modified mice: pharmacology and methodology aspects. Schizophr. Bull., 2010, 36, 246-270.
61. Moser, P.C.; Hitchcock, J.M.; Lister, S.; Moran, P.M. The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res. Rev., 2000, 33, 275-307.
62. Barak, S.; Weiner, I. Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target. Pharmacol. Biochem. Behav., 2011, 99, 164-189.
63. Gogos, J.A.; Morgan, M.; Luine, V.; Santha, M.; Ogawa, S.; Pfaff, D.; Karayiorgou, M. (1998) Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc. Natl. Acad. Sci. USA, 1998, 95, 9991-9996.
64. Huotari, M.; Gogos, J.A.; Karayiorgou, M.; Koponen, O.; Forsberg, M.; Raasmaja, A.; Hyttinen, J.; Männistö, P.T. Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur. J. Neurosci., 2002, 15(2), 246-256.
65. Haasio, K.; Huotari, M.; Nissinen, E. Tissue histopathology, clinical chemistry and 580 behaviour of adult Comt-gene-disrupted mice. J. Appl. Toxicol., 2003, 23, 213-219.
66. Babovic, D.; O'Tuathaigh, C.M.; O'Sullivan, G.J.; Clifford, J.J.; Tighe, O.; Croke, D.T.; Karayiorgou, M.; Gogos, J.A.; Cotter, D.; Waddington, J.L. Exploratory and habituation phenotype of heterozygous and homozygous COMT knockout mice. Behav. Brain Res., 2007, 183, 236-239.
67. Tammimäki, A.; Käenmäki, M.; Kambur, O.; Kulesskaya, N.; Keisala, T.; Karvonen, E.; García-Horsman, J.A.; Rauvala, H.; Männistö, P.T. Effect of S-COMT deficiency on behavior and extracellular brain dopamine concentrations in mice. Psychopharmacology (Berl.), 2010, 211(4), 389-401.
68. Wang, Y.; Fang, Y.; Shen, Y.; Xu, Q. Analysis of association between the catechol-O-methyltransferase (COMT) gene and negative symptoms in chronic schizophrenia. Psychiatry Res., 2010, 179, 147-150.
69. Kamath, V.; Moberg, P.J.; Gur, R.E.; Doty, R.L.; Turetsky, B.I. Effects of the Val(158)Met catechol-O-methyltransferase gene polymorphism on olfactory processing in schizophrenia. Behav. Neurosci., 2011, 126(1), 209-215.
70. Ishizuka, K.; Tajinda, K.; Colantuoni, C.; Morita, M.; Winicki, J.; Le, C.; Lin, S.; Schretlen, D.; Sawa, A.; Cascella, N.G. Negative symptoms of schizophrenia correlate with impairment on the University of Pennsylvania smell identification test. Neurosci. Res., 2010, 66, 106-110.
71. Uçok, A.; Oztürk, M.; Duman, Z.; Saruhan-Direskeneli, G. COMT Val 158 Met polymorphism is related with interpersonal problem solving in schizophrenia. Eur. Psychiatry, 2010, 25(6), 320-322.
72. Babovic, D.; O'Tuathaigh, C.M.; O'Connor, A.M.; O'Sullivan, G.J.; Tighe, O.; Croke, D.T.; Karayiorgou, M.; Gogos, J.A.; Cotter, D.; Waddington, J.L. Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase. Neuroscience, 2008, 155, 1021-1029.
73. Seamans, J.K.; Yang, C.R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog. Neurobiol., 2004, 74, 1-58.
74. Mier, D.; Kirsch, P.; Meyer-Lindenberg, A. (2009). Neural substrates of pleiotropic action of genetic variation in COMT: a meta-analysis. Mol. Psychiatry, 2009, 15, 918-927.
75. Barnett, J.H.; Jones, P.B.; Robbins, T.W.; Muller, U. Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls. Mol. Psychiatry, 2007, 12(5), 502-509.
76. Dumontheil, I.; Roggeman, C.; Ziermans, T.; Peyrard-Janvid, M.; Matsson, H.; Kere, J.; Klingberg, T. Influence of the COMT genotype on working memory and brain activity changes during development. Biol. Psychiatry, 2011, 70(3), 222-229.
77. Leitman, D.I.; Sehatpour, P.; Higgins, B.A.; Foxe, J.J.; Silipo, G.; Javitt, D.C. Sensory deficits and distributed hierarchical dysfunction in schizophrenia. Am. J. Psychiatry, 2010, 167, 818-827.
78. Lu, B.Y.; Martin, K.E.; Edgar, J.C.; Smith, A.K.; Lewis, S.F.; Escamilla, M.A.; Miller, G.A.; Canive, J.M. Effect of catechol O-methyltransferase Val(158)Met polymorphism on the p50 gating endophenotype in schizophrenia. Biol. Psychiatry, 2007, 62, 822-825.
79. Kang, C.; Xu, X.; Liu, H.; Yang, J. Association study of catechol-o-methyltransferase (COMT) gene Val158Met polymorphism with auditory P300 in Chinese Han patients with schizophrenia. Psychiatry Res., 2010, 180, 153-155.
80. Shaikh, M.; Hall, M.H.; Schulze, K.; Dutt, A.; Walshe, M.; Williams, I.; Constante, M.; Picchioni, M.; Toulopoulou, T.; Collier, D.; Rijsdijk, F.; Powell, J.; Arranz, M.; Murray, R.M.; Bramon, E. Do COMT, BDNF, and NRG1 polymorphisms influence P50 sensory gating in psychosis? Psychol. Med., 2011, 41, 263-276.
81. Thaker, G.K.; Wonodi, I.; Avila, M.T.; Hong, L.E.; Stine, O.C. Catechol O-methyltransferase polymorphism and eye tracking in schizophrenia: a preliminary report. Am. J. Psychiatry, 2004, 161, 2320-2322.
82. Haraldsson, H.M.; Ettinger, U.; Magnusdottir, B.B.; Sigmundsson, T.; Sigurdsson, E.; Ingason, A.; Petursson, H. COMT Val(158)Met genotype and smooth pursuit eye movements in schizophrenia. Psychiatry Res., 2009, 169, 173-175.
83. Crofts, H.S.; Dalley, J.W.; Collins, P.; Van Denderen, J.C.; Everitt, B.J.; Robbins, T.W.; Roberts, A.C. Differential effects of 6-OHDA lesions of the frontal cortex and caudate nucleus on the ability to acquire an attentional set. Cereb. Cortex, 2001, 11, 1015-1026.
84. O'Tuathaigh, C.M.; Hryniewiecka, M.; Behan, A.; Tighe, O.; Coughlan, C.; Desbonnet, L.; Cannon, M.; Karayiorgou, M.; Gogos, J.A.; Cotter, D.R.; Waddington, J.L. Chronic adolescent exposure to -9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes. Neuropsychopharmacology, 2010, 35, 2262-2273.
85. Gottesman, I.; Gould, T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry, 2003, 160, 636-645.
86. Wright, I.C.; Rabe-Hesketh, S.; Woodruff, P.W.; David, A.S.; Murray, R.M.; Bullmore, E.T. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry, 2000, 157(1), 16-25.
87. Honea, R.; Crow, T.J.; Passingham, D.; Mackay, C.E. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am. J. Psychiatry, 2005, 162(12), 2233-2245.
88. Keshavan, M.S.; Tandon, R.; Boutros, N.N.; Nasrallah, H.A. Schizophrenia, just the facts: what we know in 2008 Part 3: neurobiology. Schizophr. Res., 2008, 106(2-3), 89-107.
89. Vita, A.; Dieci, M.; Silenzi, C.; Tenconi, F.; Giobbio, G.M.; Invernizzi, G. Cerebral ventricular enlargement as a generalized feature of schizophrenia: a distribution analysis on 502 subjects. Schizophr. Res., 2000, 44(1), 25-34.
90. Bertolino, A.; Blasi, G. The genetics of schizophrenia. Neuroscience, 2009, 164, 288-299.
91. Di Giorgio, A.; Caforio, G.; Blasi, G.; Taurisano, P.; Fazio, L.; Romano, R.; Ursini, G.; Gelao, B.; Lo Bianco, L.; Papazacharias, A.; Sinibaldi, L.; Popolizio, T.; Bellomo, A.; Bertolino, A. Catechol-o-methyltransferase Val158Met association with parahippocampal physiology during memory encoding in schizophrenia. Psychol. Med., 2011, 41, 1721-1731.
92. Ho, B.C.; Wassink, T.H.; O'Leary, D.S.; Sheffield, V.C.; Andreasen, N.C. Catechol-O-methyl transferase Val(158)Met gene polymorphism in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow. Mol. Psychiatry, 2005, 10, 287-298.
93. Dutt, A.; McDonald, C.; Dempster, E.; Prata, D.; Shaikh, M.; Williams, I.; Schulze, K.; Marshall, N.; Walshe, M.; Allin, M.; Collier, D.; Murray, R.; Bramon, E. The effect of COMT, BDNF, 5-HTT, NRGI and DTNBP1 genes on hippocampal and lateral ventricular volume in psychosis. Psychol. Med., 2009, 39, 1783-1797.
94. Zinkstok, J.; Schmitz, N.; van Amelsvoort, T.; Moeton, M.; Baas, F.; Linszen, D. Genetic variation in COMT and PRODH is associated with brain anatomy in patients with schizophrenia. Genes Brain Behav., 2008, 7, 61-69.
95. Crespo-Facorro, B.; Roiz-Santianez, R.; Pelayo-Teran, J.M.; Perez- Iglesias, R.; Carrasco-Marín E, González-Mandly, A.; Jorge, R.; Vázquez-Barquero, J.L. Low-activity allele of catechol-methyltransferase (COMTL) is associated with increased lateral ventricles in patients with first episode non-affective psychosis. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31, 1514-1518.
96. Taylor, W.D.; Zuchner, S.; Payne, M.E.; Messer, D.F.; Doty, T.J.; MacFall, J.R.; Beyer, J.L.; Krishnan, K.R. The COMT Val158Met polymorphism and temporal lobe morphometry in healthy adults. Psychiatry Res., 2007, 155, 173-177.
97. Honea, R.; Verchinski, B.A.; Pezawas, L.; Kolachana, B.S.; Callicott, J.H.; Mattay, V.S.; Weinberger, D.R.; Meyer-Lindenberg, A. Impact of interacting functional variants in COMT on regional gray matter volume in human brain. Neuroimage, 2009, 45(1), 44-51.
98. Mier, D.; Kirsch, P.; Meyer-Lindenberg, A. Neural substrates of pleiotropic action of genetic variation in COMT: a meta-analysis. Mol. Psychiatry, 2009, 15, 918-927.
99. Takizawa, R.; Hashimoto, K.; Tochigi, M.; Kawakubo, Y.; Marumo, K.; Sasaki, T.; Fukuda, M.; Kasai, K. Association between sigma-1 receptor gene polymorphism and prefrontal hemodynamic response induced by cognitive activation in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33(3), 491-498.
100. Eisenberg, D.P.; Sarpal, D.; Kohn, P.D.; Meyer-Lindenberg, A.; Wint, D.; Kolachana, B.; Apud, J.; Weinberger, D.R.; Berman, K.F. Catechol-O-methyltransferase valine(158)methionine genotype and resting regional cerebral blood flow in medication-free patients with schizophrenia. Biol. Psychiatry, 2009, 67, 287-290.
101. Ehlis, A.C.; Reif, A.; Herrmann, M.J.; Lesch, K.P.; Fallgatter, A.J. Impact of catechol-O-methyltransferase on prefrontal brain functioning in schizophrenia spectrum disorders. Neuropsychopharmacology, 2007, 32(1), 162-170.
102. Meyer-Lindenberg, A.; Kohn, P.D.; Kolachana, B.; Kippenhan, S.; McInerney-Leo, A.; Nussbaum, R.; Weinberger, D.R.; Berman, K.F. Midbrain dopamine and prefrontal function in humans: Interaction and modulation by COMT genotype. Nat. Neurosci., 2005, 8, 594-596.
103. Mueller, E.M.; Makeig, S.; Stemmler, G.; Hennig, J.; Wacker, J. Dopamine effects on human error processing depend on catechol- O-methyltransferase VAL158MET genotype. J. Neurosci., 2011, 31(44), 15818-15825.
104. Kotler, M.; Barak, P.; Cohen, H.; Averbuch, I.E.; Grinshpoon, A.; Gritsenko, I.; Nemanov, L.; Ebstein, R.P. Homicidal behaviour in schizophrenia associated with a genetic polymorphism determining low catechol O-methyltransferase (COMT) activity. Am. J. Med. Genet., 1999, 88, 628-633.
105. Lachman, H.M.; Papolos, D.F.; Saito, T.; Yu, Y.M.; Szumlanski, C.L.; Weinshilboum, R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application toneuropsychiatric disorders, Pharmacogenetics, 1996, 6, 243-250.
106. Strous, R.D.; Bark, N.; Parsia, S.S.; Volavka, J.; Lachman, H.M. Analysis of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association with aggressive and antisocial behaviour. Psychiatry Res., 1997, 69, 71-77.
107. Tosato, S.; Bonetto, C.; Di Forti, M.; Collier, D.; Cristofalo, D.; Bertani, M.; Zanoni, M.; Marrella, G.; Lazzarotto, L.; Lasalvia, A.; De Gironcoli, M.; Tansella, M.; Dazzan, P.; Murray, R.; Ruggeri, M. Effect of COMT genotype on aggressive behaviour in a community cohort of schizophrenic patients. Neurosci. Lett., 2011, 495, 17-21.
108. Hong, J.P.; Lee, J.S.; Chung, S.; Jung, J.; Yoo, H.K.; Chang, S.M.; Kim, C.Y. New functional single nucleotide polymorphism (Ala72Ser) in the COMT gene is associated with aggressive behavior in male schizophrenia. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2008, 147B(5), 658-660.
109. Soyka, M. Neurobiology of aggression and violence in schizophrenia. Schizophr. Bull., 2011, 37(5), 913-920.
110. Fernandes, C.; Paya-Cano, J.L.; Sluyter, F.; D'Souza, U.; Plomin, R.; Schalkwyk, L.C. Hippocampal gene expression profiling across eight mouse inbred strains: towards understanding the molecular basis for behaviour. Eur. J. Neurosci., 2004, 19(9), 2576-2582.
111. Woodward, N.D.; Jayathilake, K.; Meltzer, H.Y. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr. Res., 2007, 90, 86-96.
112. Weickert, T.W.; Goldberg, T.E.; Mishara, A.; Apud, J.A.; Kolachana, B.S.; Egan, M.F.; Weinberger, D.R. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol. Psychiatry, 2004, 56, 677-682.
113. Kang, C.Y.; Xu, X.F.; Shi, Z.Y.; Yang, J.Z.; Liu, H.; Xu, H.H. Interaction of catechol-O-methyltransferase (COMT) Val108/158 Met genotype and risperidone treatment in Chinese Han patients with schizophrenia. Psychiatry Res., 2010, 176(1), 94-95.
114. Arseneault, L.; Cannon, M.; Witton, J.; Murray, R.M. Causal association between cannabis and psychosis: examination of the evidence. Br. J. Psychiatry, 2004, 184, 110-117.
115. Henquet, C.; Murray, R.; Linszen, D.; van Os, J. The environment and schizophrenia: the role of cannabis use. Schizophr. Bull., 2005, 31, 608-612.
116. Moore, T.H.; Zammit, S.; Lingford-Hughes, A. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet, 2007, 370, 319-328.
117. Caspi, A.; Moffitt, T.E.; Cannon, M.; McClay, J.; Murray, R.; Harrington, H.; Taylor, A.; Arseneault, L.; Williams, B.; Braithwaite, A.; Poulton, R.; Craig, I.W. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol. Psychiatry, 2005, 57, 1117-1127.
118. Costas, J.; Sanjuan, J.; Ramos-Rios, R.; Paz, E.; Agra, S.; Tolosa, A.; Páramo, M.; Brenlla, J.; Arrojo, M. Interaction between COMT haplotypes and cannabis in schizophrenia: a case-only study in two samples from Spain. Schizophr. Res., 2011, 127, 22-27.
119. van Winkel, R. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch. Gen. Psychiatry, 2011, 68, 148-157.
120. Henquet, C.; Rosa, A.; Krabbendam, L.; Papiol, S.; Fananas, L.; Drukker, M.; Ramaekers, J.G.; van Os, J. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology, 2006, 31, 2748-2757.
121. Pelayo-Terán, J.M.; Pérez-Iglesias, R.; Mata, I.; Carrasco-Marín, E.; Vázquez-Barquero, J.L.; Crespo-Facorro, B. Catechol-O- methyltransferase (COMT) Val158Met variations and cannabis use in first-episode non-affective psychosis: clinical-onset implications. Psychiatry Res., 2010, 179(3), 291-296.
122. Zammit, S.; Spurlock, G.; Williams, H.; Norton, N.; Williams, N.; O'Donovan, M.C.; Owen, M.J. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br. J. Psychiatry, 2007, 191, 402-407.
123. Estrada, G.; Fatjo-Vilas, M.; Munoz, M.J.; Pulido, G.; Minano, M.J.; Toledo, E.; Illa, J.M.; Martín, M.; Miralles, M. L.; Miret, S.; Campanera, S.; Bernabeu, C.; Navarro, M.E.; Fañanás, L. Cannabis use and age at onset of psychosis: further evidence of interaction with COMT Val158Met polymorphism. Acta Psychiatr. Scand., 2011, 123, 485-492.
124. Zammit, S.;Owen, M. J.; Evans, J.; Heron, J.; Lewis, G. Cannabis, COMT and psychotic experiences. Br. J. Psychiatry, 2011, 199, 380-385.
125. O'Tuathaigh, C.M.; Clarke, G.; Walsh, J.; Desbonnet, L.; Petit, E.; O'Leary, C.; Tighe, O.; Clarke, N.; Karayiorgou, M.; Gogos, J.A.; Dinan, T.G.; Cryan, J.F.; Waddington, J.L. Genetic vs pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes. Int. J. Neuropsychopharmacol., 2011, 11, 1-12.
126. Prata, D.P.; Mechelli, A.; Fu, C.H.; Picchioni, M.; Kane, F.; Kalidindi, S.; McDonald, C.; Howes, O.; Kravariti, E.; Demjaha, A.; Toulopoulou, T.; Diforti, M.; Murray, R.M.; Collier, D.A.; McGuire, P.K. Opposite effects of catechol-Omethyltransferase Val158Met on cortical function in healthy subjects and patients with schizophrenia. Biol. Psychiatry, 2009, 65, 473-480.
127. Caldú, X.; Vendrell, P.; Bartrés-Faz, D.; Clemente, I.; Bargalló, N.; Jurado, M.A.; Serra-Grabulosa, J.M.; Junqué, C. Impact of the COMT Val108/158 Met and DAT genotypes on prefrontal function in healthy subjects. Neuroimage, 2007, 37(4), 1437-1444.
128. Hoenicka, J.; Garrido, E.; Ponce, G.; Rodríguez-Jiménez, R.; Martínez, I.; Rubio, G.; Jiménez-Arriero, M.A.; Palomo, T. Sexually dimorphic interaction between the DRD1 and COMT genes in schizophrenia. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2010, 153B(4), 948-954.
129. Stelzel, C.; Basten, U.; Montag, C.; Reuter, M.; Fiebach, C.J. Effects of dopamine-related gene-gene interactions on working memory component processes. Eur. J. Neurosci., 2009, 29(5), 1056-1063.
130. Reuter, M.; Peters, K.; Schroeter, K.; Koebke, W.; Lenardon, D.; Bloch, B.; Hennig, J. The influence of the dopaminergic system on cognitive functioning: a molecular genetic approach. Behav. Brain Res., 2005, 164, 93-99.
131. Reuter, M.; Schmitz, A.; Corr, P.; Hennig, J. Molecular genetics support Gray's personality theory: the interaction of COMT and DRD2 polymorphisms predicts the behavioral approach system. Int. J. Neuropsychopharmacol., 2006, 9, 155-166.
132. Buckholtz, J.W.; Sust, S.; Tan, H.Y.; Mattay, V.S.; Straub, R.E.; Meyer-Lindenberg, A.; Weinberger, D. R.;Callicott, J. H. fMRI evidence for functional epistasis between COMT and RGS4. Mol. Psychiatry, 2007, 12(10), 893-895.
133. Tan, H.Y.; Chen, A.G.; Chen, Q.; Browne, L.B.; Verchinski, B.; Kolachana, B.; Zhang, F.; Apud, J.; Callicott, J.H.; Mattay, V.S.; Weinberger, D.R. Epistatic interactions of AKT1 on human medial temporal lobe biology and pharmacogenetic implications. Mol. Psychiatry, 2011, [Epub ahead of print].
134. El-Hage, W.; Phillips, M.L.; Radua, J.; Gohier, B.; Zelaya, F.O.; Collier, D.A.; Surguladze, S.A. Genetic modulation of neural response during working memory in healthy individuals: interaction of glucocorticoid receptor and dopaminergic genes. Mol. Psychiatry, 2011, [Epub ahead of print].
135. Nixon, D.C.; Prust, M.J.; Sambataro, F.; Tan, H.Y.; Mattay, V.S.; Weinberger, D.R.; Callicott, J.H. Interactive effects of DAOA (G72) and catechol-O-methyltransferase on neurophysiology in prefrontal cortex. Biol. Psychiatry, 2011, 69(10), 1006-1008.
136. Adler, C.H.; Singer, C.; O'Brien, C.; Hauser, R.A.; Lew, M.F.; Marek, K.L.; Dorflinger, E.; Pedder, S.; Deptula, D.; Yoo, K. Randomized, placebo controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch. Neurol., 1998, 55, 1089-1095.
137. Kaakkola, S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs, 2000, 59, 1233-1250.
138. Tunbridge, E.M.; Bannerman, D.M.; Sharp, T.; Harrison, P.J. Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat. J. Neurosci., 2004, 24, 5331-5335.
139. Apud, J.A.; Weinberger, D.R. Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors. CNS Drugs, 2007, 21(7), 535-557.
140. Apud, J.A.; Mattay, V.; Chen, J.; Kolachana, B.S.; Callicott, J.H.; Rasetti, R.; Alce, G.; Iudicello, J.E.; Akbar, N.; Egan, M.F.; Goldberg, T.E.; Weinberger, D.R. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology, 2007, 32(5), 1011-1020.
141. Roussos, P.; Giakoumaki, S.G.; Bitsios, P. Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c/g polymorphism. Biol. Psychiatry, 2009, 66(11), 997-1004.
142. Tandon, R.; Nasrallah, H.A.; Keshavan, M.S. Schizophrenia, "just the facts" 5. Treatment and prevention Past present, and future. Schizophr. Res., 2010, 122, 1-23.
143. Giakoumaki, S.; Tsapakis, E.M.; Roussos, P.; Chrysoulaki, A.; Kopsahili, I.; Bitsios, P. Single dose tolcapone administration improves working memory and sensorimotor gating in psychotic patients. Schizophr. Res., 2010, 117(2-3), 266.
144. Bitsios, P.; Roussos, P. Tolcapone, COMT polymoprhisms and pharmacogenomic treatment of schizophrenia. Pharmacogenomics, 2011, 12(4), 559-566.
145. Muglia, P. From genes to therapeutic targets for psychiatric disorders-what to expect? Curr. Opin. Pharmacol., 2011, 11(5), 563-571.
146. Karam, C.S.; Ballon, J.S.; Bivens, N.M.; Freyberg, Z.; Girgis, R.R.; Lizardi-Ortiz, J.E.; Markx, S.; Lieberman, J.A.; Javitch, J.A. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol. Sci., 2010, 31(8), 381-390.